×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: Sleep and Circadian Dysfunction in Alzheimer's Disease
mechanism
8,066 words
KG: Sleep and Circadian Dysfunction in Alzheimer's Disease
2026-03-26
kind:mechanism
section:mechanisms
state:published
Contents
Sleep and Circadian Dysfunction in Alzheimer's Disease
⚙
Mechanism Info
Name
Sleep and Circadian Dysfunction in Alzheimer's Disease
Summary
Comprehensive mechanism linking sleep architecture disruptions, circadian rhythm disturbances, and glymphatic dysfunction to Alzheimer's disease pathogenesis
Knowledge Graph
Related Hypotheses (30)
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.66
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.46
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
LRP1-Dependent Tau Uptake Disruption
Score: 0.44
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.43
VCP-Mediated Autophagy Enhancement
Score: 0.41
Extracellular Vesicle Biogenesis Modulation
Score: 0.34
Synaptic Vesicle Tau Capture Inhibition
Score: 0.34
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
Aquaporin-4 Polarization Rescue
Score: 0.51
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Circadian Clock-Autophagy Synchronization
Score: 0.55
Temporal Decoupling via Circadian Clock Reset
Score: 0.52
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.48
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.47
Show 25 more
Related Analyses (30)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.95
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
s:** - Test whether HCN1 knockout specifically in EC layer I
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated
clinical · proposed · Score: 0.40
Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecu
clinical · proposed · Score: 0.40
Cholinergic System Dysfunction in DLB — Mechanisms and Thera
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Epigenetic Regulation Dysfunction in Alzheimer's and Parkins
clinical · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Gap Junction Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Lifestyle Intervention Mechanisms in Alzheimer's Disease
validation · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
TREM2 Agonist Therapies for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Tau Immunotherapy for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Sodium Oligomannate (GV-971) for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Siponimod for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Nanomedicine Approaches to Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Nanomedicine for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Memantine - NMDA Antagonist for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Kamuvudine-9: NRTI for Alzheimer's Disease Neuroinflamm
therapeutic · Pages share 18 hypotheses
Ferulic Acid Carbamate Derivatives for Alzheimer's Dise
therapeutic · Pages share 18 hypotheses
Disease-Modifying Therapies for Alzheimer's Disease
therapeutics · Pages share 18 hypotheses
CAR-T Cell Therapy for Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
CAR-A (Chimeric Antigen Receptor) Astrocyte Therapy for
therapeutic · Pages share 20 hypotheses
CAR-A Therapy - Chimeric Antigen Receptor Astrocytes fo
treatment · Pages share 18 hypotheses
CAR-A Therapy — Chimeric Antigen Receptor Astrocytes fo
treatment · Pages share 18 hypotheses
Bumetanide — Alzheimer's Disease
therapeutic · Pages share 18 hypotheses
Show 10 more